Effect of IL-17 in the development of colon cancer in mice

Yang,Lijuan; Liu,Hao; Zhang,Lili; Hu,Jie; Chen,Haixia; Wang,Lei; Yin,Xiaolin; Li,Quanhai; Qi,Yixin

doi:10.3892/ol.2016.5329

Effect of IL-17 in the development of colon cancer in mice

Authors:
- Lijuan Yang
- Hao Liu
- Lili Zhang
- Jie Hu
- Haixia Chen
- Lei Wang
- Xiaolin Yin
- Quanhai Li
- Yixin Qi
View Affiliations

Affiliations: Department of Immunology, College of Basic Medical Sciences, Hebei Medical University, Shijiazhuang, Hebei 050017, P.R. China, Department of the Nuclear Medicine, The First Affiliated Hospital of Hebei Medical University, Shijiazhuang, Hebei 050031, P.R. China, The Second Hospital of Shijiazhuang, Hebei Medical University, Shijiazhuang, Hebei 050000, P.R. China, School of Nursing, Hebei Medical University, Shijiazhuang, Hebei 050000, P.R. China, Department of Electroencephalogram, Xingtai People's Hospital, Xingtai, Hebei 054031, P.R. China, Department of Pathogenic Biology and Immunology, Cangzhou Medical College, Cangzhou, Hebei 061001, P.R. China, Department of General Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050011, P.R. China
Published online on: October 31, 2016 https://doi.org/10.3892/ol.2016.5329
Pages: 4929-4936
Copyright: © Yang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cytokine therapy is commonly used for tumor immunotherapy. Although early studies focused directly on the tumor, current investigations are more attentive of the tumor microenvironment. Various immune cells and related cytokines in the tumor microenvironment play an important role in the occurrence and development of tumor. Interleukin (IL)‑17 is the characteristic cytokine produced by Th17 cells. IL‑17 has been associated with various immune responses. The results of previous studies showed that IL‑17 can significantly reduce the size of transplanted tumors in tumor‑bearing mice, albeit it has no effect on the survival time of mice. By investigating the effect of IL‑17 in the number and distribution of lymphocyte infiltration in tumor tissues, the expression of cytokines and transcription factors associated with the subsets of CD4+T cells in tumor tissues, the distribution of subsets of spleen lymphocyte in tumor‑bearing mice, a preliminary investigation of the possible antitumor mechanism of IL‑17 was performed. In conclusion, the antitumor effect of IL‑17 gene transfection in the colon cancer of mice may be associated with the mechanisms whereby IL‑17 gene transfection can change the distribution of different subsets of spleen lymphocytes in mice. IL‑17 gene transfection can increase the number of lymphocyte infiltration in tumor tissues. IL‑17 gene transfection can promote the high expression of interferon‑γ in tumor tissue, while reducing the expression of IL‑10 and IL‑13 factors, thus exerting an antitumor effect.

View Figures

View References

1	Yang TM: Clinical pathological features and survival rate of 116 cases of colorectal cancer. Chin J Med Guide. 16:602–603. 2014.
2	Zhao S and Xue B: Clinical and pathological features of rectal cancer in young patients. Mod Oncol. 21:1296–1298. 2013.
3	Zhang C, Wang Q-T, Liu H, Zhang ZZ and Huang WL: Advancement and prospects of tumor gene therapy. Chin J Cancer. 30:182–188. 2011. View Article : Google Scholar : PubMed/NCBI
4	Hou L-N, He X-H and Zhang Z-X: The present situation and outlook of the treatment of tumor with cytokine gene. J Clin Exp Med. 7:145–147. 2008.
5	Sung SY, Hsieh CL, Wu D, Chung LW and Johnstone PA: Tumor microenvironment promotes cancer progression, metastasis, and therapeutic resistance. Curr Probl Cancer. 31:36–100. 2007. View Article : Google Scholar : PubMed/NCBI
6	Nelson D, Fisher S and Robinson B: The ‘Trojan Horse’ approach to tumor immunotherapy: Targeting the tumor microenvironment. J Immunol Res. 2014:7890692014. View Article : Google Scholar : PubMed/NCBI
7	Egeblad M, Nakasone ES and Werb Z: Tumors as organs: Complex tissues that interface with the entire organism. Dev Cell. 18:884–901. 2010. View Article : Google Scholar : PubMed/NCBI
8	Jie L, Zhou X-H, Qian S, et al: The function of IL-17 family and their roles in related diseases. Curr Immunol. 34:262–265. 2014.
9	Korn T, Bettelli E, Oukka M and Kuchroo VK: IL-17 and Th17 Cells. Annu Rev Immunol. 27:485–517. 2009. View Article : Google Scholar : PubMed/NCBI
10	Fossiez F, Djossou O, Chomarat P, Flores-Romo L, Ait-Yahia S, Maat C, Pin JJ, Garrone P, Garcia E, Saeland S, et al: T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines. J Exp Med. 183:2593–2603. 1996. View Article : Google Scholar : PubMed/NCBI
11	Wakita D, Sumida K, Iwakura Y, Nishikawa H, Ohkuri T, Chamoto K, Kitamura H and Nishimura T: Tumor-infiltrating IL-17-producing gammadelta T cells support the progression of tumor by promoting angiogenesis. Eur J Immunol. 40:1927–1937. 2010. View Article : Google Scholar : PubMed/NCBI
12	He D, Li H, Yusuf N, Elmets CA, Li J, Mountz JD and Xu H: IL-17 promotes tumor development through the induction of tumor promoting microenvironments at tumor sites and myeloid-derived suppressor cells. J Immunol. 184:2281–2288. 2010. View Article : Google Scholar : PubMed/NCBI
13	Dhodapkar KM, Barbuto S, Matthews P, Kukreja A, Mazumder A, Vesole D, Jagannath S and Dhodapkar MV: Dendritic cells mediate the induction of polyfunctional human IL17-producing cells (Th17-1 cells) enriched in the bone marrow of patients with myeloma. Blood. 112:2878–2885. 2008. View Article : Google Scholar : PubMed/NCBI
14	Wang L, Yi T, Kortylewski M, Pardoll DM, Zeng D and Yu H: IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. J Exp Med. 206:1457–1464. 2009. View Article : Google Scholar : PubMed/NCBI
15	Hirahara N, Nio Y, Sasaki S, Minari Y, Takamura M, Iguchi C, Dong M, Yamasawa K and Tamura K: Inoculation of human interleukin-17 gene-transfected Meth-A fibrosarcoma cells induces T cell-dependent tumor-specific immunity in mice. Oncology. 61:79–89. 2001. View Article : Google Scholar : PubMed/NCBI
16	Benchetrit F, Ciree A, Vives V, Warnier G, Gey A, Sautès-Fridman C, Fossiez F, Haicheur N, Fridman WH and Tartour E: Interleukin-17 inhibits tumor cell growth by means of a T-cell-dependent mechanism. Blood. 99:2114–2121. 2002. View Article : Google Scholar : PubMed/NCBI
17	Hirahara N, Nio Y, Sasaki S, Takamura M, Iguchi C, Dong M, Yamasawa K, Itakura M and Tamura K: Reduced invasiveness and metastasis of Chinese hamster ovary cells transfected with human interleukin-17 gene. Anticancer Res 20 (5A). 3137–3142. 2000.
18	Martin-Orozco N, Muranski P, Chung Y, Yang XO, Yamazaki T, Lu S, Hwu P, Restifo NP, Overwijk WW and Dong C: T helper 17 cells promote cytotoxic T cell activation in tumor immunity. Immunity. 31:787–798. 2009. View Article : Google Scholar : PubMed/NCBI
19	Yang ZZ, Novak AJ, Ziesmer SC, Witzig TE and Ansell SM: Malignant B cells skew the balance of regulatory T cells and TH17 cells in B-cell non-Hodgkin's lymphoma. Cancer Res. 69:5522–5530. 2009. View Article : Google Scholar : PubMed/NCBI
20	Horlock C, Stott B, Dyson PJ, Morishita M, Coombes RC, Savage P and Stebbing J: The effects of trastuzumab on the CD4+CD25+FoxP3+ and CD4+IL17A+ T-cell axis in patients with breast cancer. Br J Cancer. 100:1061–1067. 2009. View Article : Google Scholar : PubMed/NCBI
21	Muranski P, Boni A, Antony PA, Cassard L, Irvine KR, Kaiser A, Paulos CM, Palmer DC, Touloukian CE, Ptak K, et al: Tumor-specific Th17-polarized cells eradicate large established melanoma. Blood. 112:362–373. 2008. View Article : Google Scholar : PubMed/NCBI
22	Sfanos KS, Bruno TC, Maris CH, Xu L, Thoburn CJ, DeMarzo AM, Meeker AK, Isaacs WB and Drake CG: Phenotypic analysis of prostate-infiltrating lymphocytes reveals TH17 and Treg skewing. Clin Cancer Res. 14:3254–3261. 2008. View Article : Google Scholar : PubMed/NCBI
23	Dougan M and Dranoff G: Inciting inflammation: The RAGE about tumor promotion. J Exp Med. 205:267–270. 2008. View Article : Google Scholar : PubMed/NCBI
24	Kryczek I, Wei S, Szeliga W, Vatan L and Zou W: Endogenous IL-17 contributes to reduced tumor growth and metastasis. Blood. 114:357–359. 2009. View Article : Google Scholar : PubMed/NCBI
25	Radosavljevic G, Ljujic B, Jovanovic I, Srzentic Z, Pavlovic S, Zdravkovic N, Milovanovic M, Bankovic D, Knezevic M, Acimovic LJ, et al: Interleukin-17 may be a valuable serum tumor marker in patients with colorectal carcinoma. Neoplasma. 57:135–144. 2010. View Article : Google Scholar : PubMed/NCBI
26	Zhang J-J and Zheng W-M: The relationship of IL-13 and its receptor to malignant tumor. Foreign Med Sci Oncol Sect. 32:736–739. 2005.
27	Terabe M, Park JM and Berzofsky JA: Role of IL-13 in regulation of anti-tumor immunity and tumor growth. Cancer Immunol Immunother. 53:79–85. 2004. View Article : Google Scholar : PubMed/NCBI